Dieterich H, Kemp C, Vaidyanathan S, et al. 2006. Aliskiren, the ﬁrst in a new class of orally effective renin inhibitors, has no clinically signiﬁcant drug interactions with digoxin in healthy volunteers. Clin Pharmacol Ther, 79:111–24. Dieterle W, Corynen S, Mann J. 2004. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol, 58:433–6. Dieterle W, Corynen S, Vaidyanathan S, et al. 2005. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther, 43:527–35. Fisher NDL, Hollenberg NK. 2005. Renin inhibition: what are the thera- peutic opportunities? J Am Soc Nephrol, 16:592–9. Flather MD, Yusuf S, Kober L, et al. 2000. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet, 355:1575–81. Fukamizu A, Sugimura K, Takimoto E, et al. 1993. Chimeric renin- angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. J Biol Chem, 268:11617–21. Ganten D, Wagner J, Zeh K, et al. 1992. Species speciﬁcity of renin kinet- ics in transgenic rats harboring the human renin and angiotensinogen genes. Proc Natl Acad Sci USA, 89:7806–10. Gradman AH, Schmieder RE, Lins RL, et al. 2005. Aliskiren, a novel, orally-effective renin inhibitor, provides antihypertensive efﬁcacy and placebo-like tolerability similar to an AT1-receptor blocker in hypertensive patients. Circulation, 111:1012–8. Gross F, Lazar J, Orth H. 1971. Inhibition of the renin-angiotensinogen reaction by pepstatin. Science, 175:656. Herron J, Mitchell J, Oh B, et al. 2006. The novel renin inhibitor aliskiren is not associated with rebound effects on blood pressure or plasma renin activity following treatment withdrawal. J Clin Hypertens, 8(Suppl A):A93. Hollenberg NK, Fisher ND, Price DA. 1998. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharma- cological interruption of the renin system. Hypertension, 32:387–92. Julius S, Kjeldsen SE, Weber M, et al. for the VALUE trial group. 2004. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE ran- domised trial. Lancet, 363:2022–31. Kario K, Pickering TG, Umeda Y, et al. 2003. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives. A prospective study. Circulation, 107:1401–6. Kim S, Iwao H. 2000. Molecular and cellular mechanisms of angioten- sin II-mediated cardiovascular and renal diseases. Pharmacol Rev, 52:11–34. Kleinbloesem CH, Weber C, Fahrner E, et al. 1993. Hemodynamics, bio- chemical effects, and pharmacokinetics of the renin inhibitor remikiren in healthy human subjects. Clin Pharmacol Ther, 53:585–92. Menard J, Boger RS, Moyse DM, et al. 1995. Dose-dependent effects of the renin inhibitor zankiren HCI after a single oral dose in mildly sodium- depleted normotensive subjects. Circulation, 91:330–8. Nguyen G, Delarue F, Burcklé C, et al. 1996. Speciﬁc receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int, 50:1897–1903. Nguyen G, Delarue F, Burcklé C, et al. 2002. Pivotal role of the renin/ prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest, 109:1417–27. Nussberger J, Wuerzner G, Jensen C, et al. 2002. Angiotensin II suppres- sion in humans by the orally active renin inhibitor aliskiren (SPP100). Comparison with enalapril. Hypertension, 39:E1–8. O’Brien E. 2006. Aliskiren: a renin inhibitor offering a new approach for the treatment of hypertension. Expert Opin Investig Drugs, 15:1269–77. O’Brien E, Barton J, Nussberger J, et al. 2007. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension, 4(9):276–84. Vascular Health and Risk Management 2007:3(6) Aliskiren in essential hypertension Pilz B, Shagdarsuren E, Wellner M, et al. 2005. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension, 46:569–76. Pool JL, Schmieder RE, Azizi M, et al. 2007. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efﬁcacy alone and in com- bination with valsartan. Am J Hypertens, 20:11–20. Rongen GA, Lenders JWM, Smits P, et al. 1995. Clinical pharmacokinetics and efﬁcacy of renin inhibitors. Clin Pharmacokinet, 29:6–14. Ruggenenti P, Perna A, Gherardi G, et al. 1999. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet, 354:359–64. Sica D, Gradman A, Lederballe O, et al. 2006. Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone or in combination with HCTZ during long-term (52-weeks) treatment of hypertension. Eur Heart J, 27(Abstract Suppl):121. Skeggs LT, Kahn JR, Lentz KE, et al. 1957. Preparation, puriﬁcation, and amino acid sequence of a polypeptide renin substrate. J Exp Med, 106:439–53. Staessen JA, Li Y, Richart T. 2006. Oral renin inhibitors. Lancet, 368:1449–56. Staessen JA, Li Y, Thijs L, Wang JG. 2005. Blood pressure reduction and cardiovascular prevention: an update including the 2003–2004 second- ary prevention trials. Hypertens Res, 28:385–407. Stanton A. 2003. Therapeutic potential of renin inhibition in the management of cardiovascular disorders. Am J Cardiovasc Drugs, 3:389–94. Stanton A, Jensen C, Nussberger J, et al. 2003. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hyperten- sion, 42:1137–43. Turnbull F. 2003. Effects of different blood-pressure-lowering regimens on major cardiovascular evets: results of prospectively-designed overviews of randomised trials. Lancet, 362:1527–35. Vaidyanathan S, Valencia J, Kemp C, et al. 2006. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int J Clin Pract, 60:1343–56. Vaidyanathan S, Jermany J, YTeh C, et al. 2007. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharma- codynamics in Japanese and Caucasian subjects. Br J Clin Pharmacol, 62(6):690–8. Vaidyanathan S, Warren V, Yeh C, et al. 2007. Pharmacokinetics, safety, and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairment. Clin Pharmacol, 47(2):192–200. Villamil A, Chrysant S, Calhoun D, et al. 2006. The novel renin inhibitor aliskiren provides effective blood pressure control in patients with hypertension when used alone or in combination with hydrochlorothi- azide. J Clin Hypertens, 8(Suppl A):A100. Wang JG, Staessen JA, Franklin SS, et al. 2005. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension, 45:907–13. Watanabe T, Barker TA, Berk BC. 2005. Angiotensin II and the endothe- lium: diverse signals and effects. Hypertension, 45:163–9. Weir M, Bush C, Zhang J, et al. 2006. Antihypertensive efﬁcacy and safety of the oral renin inhibitor aliskiren in patients with hypertension: a pooled analysis. Eur Heart J, 27(Abstract Suppl):299. Wood JM, Maibaum J, Rahuel J, et al. 2003. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun, 308:698–705. Wood JM, Schnell CR, Cumin F, et al. 2005. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens, 23:417–26. Zhao C, Vaidyanathan S, Yeh CM, et al. 2006. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet, 45:1125–34. 815